244 related articles for article (PubMed ID: 33346633)
1. The SARS-CoV-2 Cytopathic Effect Is Blocked by Lysosome Alkalizing Small Molecules.
Gorshkov K; Chen CZ; Bostwick R; Rasmussen L; Tran BN; Cheng YS; Xu M; Pradhan M; Henderson M; Zhu W; Oh E; Susumu K; Wolak M; Shamim K; Huang W; Hu X; Shen M; Klumpp-Thomas C; Itkin Z; Shinn P; Carlos de la Torre J; Simeonov A; Michael SG; Hall MD; Lo DC; Zheng W
ACS Infect Dis; 2021 Jun; 7(6):1389-1408. PubMed ID: 33346633
[TBL] [Abstract][Full Text] [Related]
2. The SARS-CoV-2 cytopathic effect is blocked with autophagy modulators.
Gorshkov K; Chen CZ; Bostwick R; Rasmussen L; Xu M; Pradhan M; Tran BN; Zhu W; Shamim K; Huang W; Hu X; Shen M; Klumpp-Thomas C; Itkin Z; Shinn P; Simeonov A; Michael S; Hall MD; Lo DC; Zheng W
bioRxiv; 2020 May; ():. PubMed ID: 32511355
[TBL] [Abstract][Full Text] [Related]
3. Repurposing old drugs as antiviral agents for coronaviruses.
Yang CW; Peng TT; Hsu HY; Lee YZ; Wu SH; Lin WH; Ke YY; Hsu TA; Yeh TK; Huang WZ; Lin JH; Sytwu HK; Chen CT; Lee SJ
Biomed J; 2020 Aug; 43(4):368-374. PubMed ID: 32563698
[TBL] [Abstract][Full Text] [Related]
4. Drugs, Metabolites, and Lung Accumulating Small Lysosomotropic Molecules: Multiple Targeting Impedes SARS-CoV-2 Infection and Progress to COVID-19.
Blaess M; Kaiser L; Sommerfeld O; Csuk R; Deigner HP
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33670304
[TBL] [Abstract][Full Text] [Related]
5. Friend or Foe? Implication of the autophagy-lysosome pathway in SARS-CoV-2 infection and COVID-19.
He W; Gao Y; Zhou J; Shi Y; Xia D; Shen HM
Int J Biol Sci; 2022; 18(12):4690-4703. PubMed ID: 35874956
[TBL] [Abstract][Full Text] [Related]
6. Anti-SARS-CoV-2 Potential of Artemisinins In Vitro.
Cao R; Hu H; Li Y; Wang X; Xu M; Liu J; Zhang H; Yan Y; Zhao L; Li W; Zhang T; Xiao D; Guo X; Li Y; Yang J; Hu Z; Wang M; Zhong W
ACS Infect Dis; 2020 Sep; 6(9):2524-2531. PubMed ID: 32786284
[TBL] [Abstract][Full Text] [Related]
7. Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro.
Pasquereau S; Nehme Z; Haidar Ahmad S; Daouad F; Van Assche J; Wallet C; Schwartz C; Rohr O; Morot-Bizot S; Herbein G
Viruses; 2021 Feb; 13(2):. PubMed ID: 33672333
[TBL] [Abstract][Full Text] [Related]
8. Cytopathic SARS-CoV-2 screening on VERO-E6 cells in a large-scale repurposing effort.
Zaliani A; Vangeel L; Reinshagen J; Iaconis D; Kuzikov M; Keminer O; Wolf M; Ellinger B; Esposito F; Corona A; Tramontano E; Manelfi C; Herzog K; Jochmans D; De Jonghe S; Chiu W; Francken T; Schepers J; Collard C; Abbasi K; Claussen C; Summa V; Beccari AR; Neyts J; Gribbon P; Leyssen P
Sci Data; 2022 Jul; 9(1):405. PubMed ID: 35831315
[TBL] [Abstract][Full Text] [Related]
9. GNS561 Exhibits Potent Antiviral Activity against SARS-CoV-2 through Autophagy Inhibition.
Bestion E; Zandi K; Belouzard S; Andreani J; Lepidi H; Novello M; Rouquairol C; Baudoin JP; Rachid M; La Scola B; Mege JL; Dubuisson J; Schinazi RF; Mezouar S; Halfon P
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062337
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of Human Coronaviruses by Antimalarial Peroxides.
Ghosh AK; Miller H; Knox K; Kundu M; Henrickson KJ; Arav-Boger R
ACS Infect Dis; 2021 Jul; 7(7):1985-1995. PubMed ID: 33783182
[TBL] [Abstract][Full Text] [Related]
11. On-target versus off-target effects of drugs inhibiting the replication of SARS-CoV-2.
Sauvat A; Ciccosanti F; Colavita F; Di Rienzo M; Castilletti C; Capobianchi MR; Kepp O; Zitvogel L; Fimia GM; Piacentini M; Kroemer G
Cell Death Dis; 2020 Aug; 11(8):656. PubMed ID: 32814759
[TBL] [Abstract][Full Text] [Related]
12. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2 Infection.
Aslam M; Ladilov Y
Cells; 2020 Aug; 9(9):. PubMed ID: 32854430
[TBL] [Abstract][Full Text] [Related]
13. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
14. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
15. Why the lower reported prevalence of asthma in patients diagnosed with COVID-19 validates repurposing EDTA solutions to prevent and manage treat COVID-19 disease.
Cashman DP
Med Hypotheses; 2020 Nov; 144():110027. PubMed ID: 32758873
[TBL] [Abstract][Full Text] [Related]
16. LY6E Restricts Entry of Human Coronaviruses, Including Currently Pandemic SARS-CoV-2.
Zhao X; Zheng S; Chen D; Zheng M; Li X; Li G; Lin H; Chang J; Zeng H; Guo JT
J Virol; 2020 Aug; 94(18):. PubMed ID: 32641482
[TBL] [Abstract][Full Text] [Related]
17. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
18. Antiviral Activity of the Propylamylatin
Brown AN; Strobel G; Hanrahan KC; Sears J
Viruses; 2021 Mar; 13(3):. PubMed ID: 33807769
[TBL] [Abstract][Full Text] [Related]
19. SARS-CoV-2 ORF7a blocked autophagy flux by intervening in the fusion between autophagosome and lysosome to promote viral infection and pathogenesis.
Li S; Li X; Liang H; Yu K; Zhai J; Xue M; Luo Z; Zheng C; Zhang H
J Med Virol; 2023 Nov; 95(11):e29200. PubMed ID: 37916857
[TBL] [Abstract][Full Text] [Related]
20. Novel Tetrahydroisoquinoline-Based Heterocyclic Compounds Efficiently Inhibit SARS-CoV-2 Infection
Wang X; Burdzhiev NT; Hu H; Li Y; Li J; Lozanova VV; Kandinska MI; Wang M
Viruses; 2023 Feb; 15(2):. PubMed ID: 36851716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
